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TEN DAYS QUADRUPLE VERSUS SEQUENTIAL THERAPY AS EMPIRICAL FIRST- 
AND SECOND-LINE TREATMENT FOR HELICOBACTER PYLORI ERADICATION: A 
RANDOMISED CROSSOVER TRIAL 
SHK Liu, IFN Hung, WK Seto, WK Leung 
 
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong 
 
INTRODUCTION: Helicobacter pylori (HP) is one of the commonest bacterial infections 
worldwide. The eradication rate of clarithromycin-based and bismuth-based therapy has been 
declining in the western world. The aim of the study was to compare the efficacy and tolerability 
of HP eradication with a 10-day sequential therapy versus quadruple therapy as empirical first- 
and second-line treatment. 
 
METHODS: Eligible HP-positive patients were randomised to receive either sequential (SEQ) 
therapy (esomeprazole 20 mg twice daily and amoxicillin 1 g twice daily for the first 5 days 
followed by esomeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and 
metronidazole 400 mg four times daily for the subsequent 5 days) for 10 days or quadruple 
(QUAD) therapy (esomeprazole 20 mg twice daily, bismuth subcitrate 120 mg four times daily, 
tetracycline 500 mg four times daily, and metronidazole 400 mg four times daily) for 10 days. All 
patients returned 8 weeks after completing the treatment for a urea breath test (UBT) to confirm 
eradication. Patients who failed the initial UBT would crossover to receive the alternate treatment 
regimen. 
 
RESULTS: A total of 391 patients were recruited into the study with 213 in the SEQ group and 
178 in the QUAD group. The baseline demographics and endoscopic diagnoses were similar in 
both groups. A total of 200 patients (93.9%) and 163 patients (91.6%) completed treatment in 
SEQ and QUAD group respectively. By perprotocol analysis, the eradication rate was 96% in 
SEQ group and 98.7% in the QUAD group (P=0.195). The eradication rate calculated by the 
intentional-to-treat was 91% (194/213) in SEQ group and 92.7% (165/178) in the QUAD group 
(P=0.348). The most common adverse events were bitter taste (1.9%) and nausea (2.2%) in SEQ 
and QUAD group respectively. There were seven cases from SEQ group crossover to receive 
QUAD therapy and two patients who initially failed QUAD therapy crossover to the SEQ therapy. 
All of the patients were successfully eradicated from HP after receiving the alternate therapy. 
 
CONCLUSIONS: Both SEQ and QUAD therapy are highly effective in HP eradication as first- 
and second-line treatment with similar mild adverse events. 
